Company Description

Azora Therapeutics, Inc. operates as a biopharmaceutical company that develops small molecule new chemical entities for the treatment of autoimmune and inflammatory diseases.

It offers treatment for dermatology and gastroenterology. The company's pipeline includes AT177, a colon‑targeted aryl hydrocarbon receptor (AhR) agonist to enable localized activation with limited systemic exposure in development for ulcerative colitis.

Azora Therapeutics, Inc. was formerly known as Meya Pharmaceuticals, Inc. and changed its name to Azora Therapeutics, Inc. in March 2019.

The company was incorporated in 2017 and is based in Encino, California.

Azora Therapeutics, Inc.

Country	United States
Founded	2017
IPO Date	Jul 30, 2018
Industry	Medical - Pharmaceuticals
Sector	Healthcare

Contact Details

Address: 4267 Valley Meadow Road Encino, California 91436 United States
Phone	(818) 276-6726
Website	azoratherapeutics.com

Stock Details

Ticker Symbol	AZR
Exchange	NASDAQ
Reporting Currency	USD
CIK Code	0001513525
CUSIP Number	054800107
ISIN Number	US0548001074